ECC-BYF III has been shown to have efficacy in a rat model of COPD by enhancing pulmonary function, reducing oxidative stress, inflammation, and mucin secretion [15,16]; however, the mechanisms underlying the effects of ECC-BYF III on AMH and COPD remains unclear. Here, AMH is linked to chronic obstructive pulmonary disease.